WO2001094618A1 - Procede de detection d'albumine saccharifiee - Google Patents
Procede de detection d'albumine saccharifiee Download PDFInfo
- Publication number
- WO2001094618A1 WO2001094618A1 PCT/JP2001/004734 JP0104734W WO0194618A1 WO 2001094618 A1 WO2001094618 A1 WO 2001094618A1 JP 0104734 W JP0104734 W JP 0104734W WO 0194618 A1 WO0194618 A1 WO 0194618A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- albumin
- serum
- glycated
- value
- saccharified
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6827—Total protein determination, e.g. albumin in urine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins
Definitions
- the present invention relates to a method for detecting a specific glycated protein in serum.
- Diabetes should be treated and detected as accurately and as early as possible.
- glycated albumin in serum has attracted attention as a short-term blood glucose control index, and an appropriate method of detecting glycated albumin is currently being sought.
- glycated albumin in serum is carried out by a so-called HPLC method (Clinical Laboratory vol 40:. 1275-1280, 1996) force s, in this method, it is difficult to process large quantities of sample, There is a problem that running costs are increased.
- the present inventors have made intensive studies to solve this problem and found that it is effective to use a glycoprotein measurement reagent that can detect glycated protein in serum by an enzymatic method. I thought. Furthermore, in order to improve the accuracy of this detection method, if the quantified value of glycated protein obtained with the glycoprotein measurement reagent is divided by the quantified value of albumin quantified in the same serum sample and corrected, this correction is performed. It was found that the value showed a very good correlation with the quantitative value of glycated albumin in serum (quantitative value by the above HPLC method).
- the problem to be solved by the present invention is to perform the regression equation using the corrected quantification method using the enzymatic method without the above-mentioned section appearing and by the HPLC method.
- the present inventor has found that the appearance of the above-mentioned section is caused by the use of an artificial type of glycated albumin standard material used for quantification by the enzymatic method. .
- saccharified albumin used in the enzymatic method is obtained by recombining a recombinant albumin or human-derived albumin fraction obtained from Escherichia coli or the like into which a gene encoding albumin has been incorporated in the presence of glucose. It is a saccharified albumin obtained by forcibly saccharifying albumin by keeping the temperature around 7 ° C. This artificial saccharified albumin aims to bind glucose to all four sugar chain binding sites present on albumin.
- the enzymatic method is performed using such conventional glycated albumin as a standard substance, there is a tendency that the results obtained by the HPLC method do not always show a good correlation.
- the number of glycated albumin saccharides originally present in at least the serum of healthy humans is less than 4, usually 1 or 2 or so.
- the quantification method of glycated albumin one molecule of glycated albumin can be recognized equally regardless of the number of sugar bonds in albumin. It is conceivable that the measured values fluctuate due to the change. Also, in order to perform saccharification perfectly when the above-mentioned forced saccharification is performed (that is, the average number of sugar bonds per molecule of albumin is approximately 4), it is necessary to keep the temperature in the presence of glucose.
- the present inventors have separated and collected glycated albumin present in the serum of a human (healthy person) and collected the glycated albumin. To use it as a reference material.
- the present invention provides a glycoprotein measurement reagent for measuring glycated protein in serum, dividing the quantitative value by the quantitative value of total albumin in the serum, and correcting the corrected value.
- a glycoprotein measurement reagent which is used as the quantitative value of glycated albumin in glycated albumin
- glycated albumin used as a standard substance is obtained by separating from the albumin fraction derived from the blood of healthy humans
- the present invention provides a method for detecting saccharified albumin, which is a saccharified albumin (hereinafter, also referred to as the present detection method).
- Healthy person means a person who is not diabetic or a diabetic border region.
- a healthy person has a fasting plasma blood glucose level of less than 11 Omg / dl, and 5 Glycated albumin derived from blood with a plasma glucose level of less than 140 mg / dl 2 hours after the glucose tolerance test (hereinafter also referred to as natural glycated albumin)
- glycated albumin present in the serum of healthy humans.
- the average number of glycated molecules per albumin molecule in albumin having four glycated sites is less than 4, It means saccharified albumin which is usually 1-2.
- the average number of sugar bonds per molecule of natural glycated albumin which can be used as a standard substance in the present detection method is generally 1 to 2, and is shown in Examples described later.
- the ratio is preferably approximately 1.3 to 2.1 (rounded to the second decimal place), in the present invention, the average of the number of sugar bonds is 1.3 to 2.1 (decimal point).
- a detection method using saccharified albumin (rounded to the second place) as a standard substance is also provided as this detection method.
- this detection method uses a glycoprotein measurement reagent and glycated protein in serum.
- Glycoprotein was quantified using a glycoprotein measurement reagent, and the resulting quantified value was divided by the quantified value of total albumin in the serum and corrected, and the corrected value was used as the quantified value of glycated albumin in the serum.
- the present invention also provides a method for detecting glycated albumin, wherein the average number of sugar bonds per molecule of glycated albumin used as a standard substance is 1.3 to 2.1.
- a means for directly separating non-glycated albumin and glycated albumin from human serum for example, a carrier in which aminophenylboronic acid is immobilized as a ligand
- a carrier in which aminophenylboronic acid is immobilized as a ligand for example, a carrier in which aminophenylboronic acid is immobilized as a ligand
- the method for producing natural saccharified albumin is not limited to this.
- a part of the saccharification site of a non-saccharified albumin molecule is protected by a protecting group or the like so that saccharification does not occur.
- Natural saccharified albumin can also be obtained by removing the protecting group and the like after the forced saccharification is performed.
- the reagent for measuring a glycoprotein using the above enzyme includes, for example, a reagent combining ketoaminooxidase or fructosamine oxidase, in which substrate specificity is recognized between protease and glycated amino acid.
- the measurement reagents are sold as so-called “Gly-Pro reagents” by Auto Corp. fructosamine reagent (manufactured by Wako Pure Chemical Industries, Ltd.) and “Gly-Pro TM Reagent”.
- Fig. 1 is a drawing examining the correlation between the glycated albumin value in serum and the corrected value obtained by the corrected enzyme method using artificial glycated albumin as a standard substance.
- Fig. 2 shows the glycated albumin in serum.
- 3 is a drawing in which a correlation between an albumin value and a correction value obtained by a correction enzyme method using natural glycated albumin as a standard substance was examined.
- Human albumin (including glycated albumin) can be obtained by separation from human serum or plasma by a generally known method. For example, proteins in human serum or plasma can be isolated by an anion exchange column. And other protein components.
- glycated albumin is separated and collected from such healthy human albumin by applying means capable of selecting non-glycated albumin and glycated albumin.
- a means for selecting this albumin for example, separation of glycated albumin and non-glycated albumin using a carrier having a ligand that can specifically adsorb either glycated albumin or non-glycated albumin as a ligand can be mentioned.
- a carrier include a carrier in which aminophenylboronic acid is immobilized as a ligand.
- the hydroxyl group of aminophenylboronic acid bound as a ligand to the carrier and the cis-diol group of glucose bound in saccharified albumin are bonded to the carrier.
- Saccharified albumin is selectively captured.
- a desired natural saccharified albumin can be produced.
- the carrier is immobilized with aminophenylphenolic acid as a ligand, for example, another substance having a cis-diol group, such as D-sorbitol, is captured by the carrier.
- the force s for example, substitution with glycated albumin, should be selected according to the specific type of the selected separation carrier, and is not limited thereto.
- the above-mentioned process for producing saccharified albumin can be used as a method for selectively producing non-glycated albumin.
- This non-glycated albumin is also very useful as a standard substance.
- the supplier of the blood used as a raw material for production may be an unhealthy person, and is preferably a healthy person).
- non-saccharified albumin usually contains natural saccharified albumin in relation to the total amount of albumin. It is contained in an amount of about 10 to 15% by mass.
- the serum of a healthy person can be used instead of the non-glycated albumin.
- Purification and collection of natural saccharified albumin from the above-mentioned fraction containing saccharified albumin can be carried out by using well-known methods widely used for purifying and collecting proteins. That is, the desired natural saccharification can be performed from the fraction containing glycated albumin by appropriately using treatment with a normal protein precipitant, ultrafiltration, gel filtration, liquid chromatography, centrifugation, electrophoresis, dialysis, etc. It can purify and collect the albumin.
- natural glycated albumin produced in this manner has an average of less than 4 glycation sites per albumin molecule among the 4 saccharification sites of albumin, usually 1 to 2 sites, More specifically, saccharified albumin is saccharified at 1.3 to 2.1 places (rounded to the second decimal place).
- This detection method is based on the premise that glycated protein in serum (which can be prepared from a blood sample by an ordinary method) is quantified using a glycoprotein measurement reagent. Force, Chikararu i-th "constant is," Young, D., Effects of drugs on cl inical laboratory t ests, 4 th ed., AACC Press, Washington, and the child to adopt a method that has been described in DC, 1995 J Can be.
- Glycoproteins in serum are digested with proteases such as pronase and proteinase K to produce fructosyl amino acids.
- proteases such as pronase and proteinase K
- fructosyl amino acids are digested with proteases such as pronase and proteinase K to produce fructosyl amino acids. 2
- ketoaminooxidase or fructosamine oxidase is acted on in the presence of oxygen to generate hydrogen peroxide
- the present detection method is characterized in that the above-mentioned natural glycated albumin is used as a standard substance in the measurement by such an enzymatic method.
- the method for quantifying the total albumin is not particularly limited, and examples thereof include an immunoturbidimetric method, a latex method, and a dye method.
- the glycated albumin value in serum can be accurately quantified and detected.
- the most preferable aspects of this detection method are: 1) the process of quantifying glycated protein in serum using natural albumin as a standard, 2) the process of quantifying total albumin in the serum, and 3) the value obtained in 1). This is to automate the three processes of the correction process of dividing by the value obtained in.
- Such an automation process can be easily performed by those skilled in the art by adjusting an existing automated quantification device for serum test according to the present detection method.
- a urine sample may be used as the sample used in the present detection method depending on the purpose of the specific test.
- the present invention provides, as a standard substance, natural glycated albumin (glycated albumin obtained by separating from an albumin fraction derived from the blood of a healthy person, or an average number of glycated bonds per molecule of glycated albumin of 1. 3 to 2.1 saccharified albumin) as a component of the kit.
- glycated albumin obtained by separating from an albumin fraction derived from the blood of a healthy person, or an average number of glycated bonds per molecule of glycated albumin of 1. 3 to 2.1 saccharified albumin
- This kit for detection requires, in addition to natural glycated albumin as described above, non-glycated albumin, and a quantification reagent for quantifying glycated protein by enzymatic method, which is used as a standard substance for detection. Can be included as a component of the kit.
- the molar ratio [B] of the glycated protein in the serum to the total albumin was measured using “Gly-Pr 0 reagent” (Gly-Pro TM Reagent: manufactured by Zenzym). Then, by calculating [B] / [A] by dividing the former [A] by the latter [B], the average number of sugar bonds per molecule of saccharified albumin of each sample was determined. Table 1 shows the results.
- the average number of glycated bonds per molecule of glycated albumin derived from the donors of samples 1 to 6 as healthy subjects was 1.3 to 2.1 (respectively, the numbers after the second decimal place are (The average value of the six samples is 2.01.)
- the average number of glycated albumin per molecule of glycated albumin in a sample from a patient with borderline diabetes or diabetes is a numerical value. It can be seen that is large and the variation is large.
- glycated albumin derived from blood of healthy subjects has a small number of sugar bonds per molecule and almost two, and is suitable as a standard substance when glycated albumin is quantified by an enzymatic method. It became clear that there was.
- the mixed gel was allowed to stand for 16 hours while refrigerated (4 ° C)
- the serum components collected on the gel were removed by pipetting from the opening of the column with a pipette.
- the mixed gel, equilibrated solution [0. 02M EP PS buffer (p H 8. 6), 0. 1 5 MN a C 1, 0. 0 1 MM g C 1 2 ] passing a 5 mL
- unadsorbed components were eluted.
- the unadsorbed component is dialyzed in a physiological saline solution 500 times the volume of the sample while stirring with a stirrer, and the dialysate is filtered using a filtration membrane (Centricon 10: Amicon). Ultrafiltration was performed at 3,000 rpm for 6 hours, and the concentration was reduced to about 1/4 (Centricone 10 was replaced with a new one every 1/2 concentration).
- the concentrate of the sample thus obtained was used as a low-value sample of saccharified albumin (non-saccharified albumin).
- the amount of natural saccharified albumin in the low-value sample of saccharified albumin was about 10 mass 0 / to the total amount of albumin. Met.
- the concentrate of the sample thus obtained was used as a high-value sample of saccharified albumin (saccharified albumin).
- the average number of sugar bonds per molecule of albumin in the high-value sample of saccharified albumin was 2.02.
- Example 1-3 provider serum a crude human albumin 2g
- a crude human albumin 2g was dissolved in an aqueous solution in 1 100 ml containing 5 mass 0/0 glucose and 0.05 mass 0/0 sodium azide The temperature was kept at 37 ° C. for 48 hours. Thereafter, this solution was dialyzed overnight in distilled water at 5 ° C. using a permeable membrane. After completion of the dialysis, the dialysate was subjected to ultrafiltration using an ultrafiltration membrane (Centricon 10: Amicon) at 3000 rpm for 6 hours, and concentrated to about 1/4 (1Z2 concentration). Each time the Sentricon 10 was replaced with a new one). The sample thus obtained was used as an artificially high sample of saccharified albumin.
- Serum was obtained from blood samples from 48 blood sample donors, and the saccharified albumin produced in the above production example was obtained using “Gly-Pr 0 reagent” (Gly-Pro TM Reagent: manufactured by Zenzam). Serum glycated protein (1) was quantified using low-value samples and artificially high-value samples as standard solutions.
- glycated albumin (2) in serum was quantified by the HP LC method (two-column method described in “Clinical Laboratory vol. 40: 1275-1280, 1996”).
- Fig. 1 is a drawing that examines the correlation between (2) and the value (%) of (3) instead of (1) above.
- the serum glycated protein (1), (1) was quantified using the low value sample and the high value sample of glycated albumin produced in the above Production Example as standard solutions.
- FIG. 1 Drawings examining the correlation between the quantified value of glycated albumin (2) in serum by the HPLC method and the value (1),, divided by the total albumin value (3) ', similar to the above, FIG.
- glycated albumin which can be a good indicator for diabetes, can be accurately and simply detected and quantified by the present detection method.
- the detection method is, in the detection of diabetes seen that force s is a very effective means.
- glycated albumin which can be a good indicator for diabetes, can be accurately and simply detected and quantified, and a very effective means for detecting diabetes is provided.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001260716A AU2001260716A1 (en) | 2000-06-07 | 2001-06-05 | Method of detecting saccharified albumin |
CA002411850A CA2411850A1 (en) | 2000-06-07 | 2001-06-05 | Method of detecting saccharified albumin |
JP2002502158A JP4847668B2 (ja) | 2000-06-07 | 2001-06-05 | 糖化アルブミンの検出方法 |
EP01934548A EP1291438A1 (en) | 2000-06-07 | 2001-06-05 | Method of detecting saccharified albumin |
US10/297,748 US20040048387A1 (en) | 2000-06-07 | 2001-06-05 | Method of detecting saccharified albumin |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000170773 | 2000-06-07 | ||
JP2000-170773 | 2000-06-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001094618A1 true WO2001094618A1 (fr) | 2001-12-13 |
Family
ID=18673433
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/004734 WO2001094618A1 (fr) | 2000-06-07 | 2001-06-05 | Procede de detection d'albumine saccharifiee |
Country Status (6)
Country | Link |
---|---|
US (1) | US20040048387A1 (ja) |
EP (1) | EP1291438A1 (ja) |
JP (1) | JP4847668B2 (ja) |
AU (1) | AU2001260716A1 (ja) |
CA (1) | CA2411850A1 (ja) |
WO (1) | WO2001094618A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007107950A (ja) * | 2005-10-12 | 2007-04-26 | Bml Inc | 糖化アルブミンの管理試料 |
JP2007163515A (ja) * | 2002-06-18 | 2007-06-28 | Asahi Kasei Pharma Kk | 糖化タンパク質測定用検量物質および標準測定法 |
EP2352020A2 (en) | 2010-01-19 | 2011-08-03 | Arkray, Inc. | Method for analyzing sample by electrophoresis and use of the same |
CN109477839A (zh) * | 2016-07-28 | 2019-03-15 | 旭化成制药株式会社 | 糖化白蛋白的测定方法 |
WO2021002371A1 (ja) | 2019-07-01 | 2021-01-07 | 旭化成ファーマ株式会社 | フェロシアン化物の酸化還元電位を大きくするプロテアーゼの安定化剤を含む糖化タンパク質測定試薬、糖化タンパク質の測定方法、糖化タンパク質測定試薬の保存方法、及び糖化タンパク質測定試薬の安定化方法 |
WO2022158556A1 (ja) * | 2021-01-23 | 2022-07-28 | 株式会社Provigate | タンパク質の糖化度を評価する方法及び装置 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109991426A (zh) * | 2019-04-03 | 2019-07-09 | 深圳市安帝宝科技有限公司 | 一种糖化血清白蛋白检测试剂盒 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61280297A (ja) * | 1985-06-04 | 1986-12-10 | Noda Sangyo Kagaku Kenkyusho | アマドリ化合物の定量法及びその定量用試薬 |
JPH0556799A (ja) * | 1990-07-04 | 1993-03-09 | Nakarai Tesuku Kk | 糖化タンパク質の検出試薬 |
EP0709457A1 (en) * | 1994-10-05 | 1996-05-01 | Kyoto Daiichi Kagaku Co., Ltd. | Fructosyl amino acid oxidase and process for producing the same |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5132230A (en) * | 1989-03-28 | 1992-07-21 | Isolab, Inc. | Primary standard and method of making secondary standards for calibration of glycated protein assays |
GB9116315D0 (en) * | 1991-07-29 | 1991-09-11 | Genzyme Ltd | Assay |
JP3850904B2 (ja) * | 1994-10-05 | 2006-11-29 | アークレイ株式会社 | フルクトシルアミノ酸オキシダーゼ及びその製造方法 |
DE69603472T2 (de) * | 1995-05-05 | 1999-12-30 | Genzyme Ltd | Bestimmung von glykierten proteinen |
-
2001
- 2001-06-05 EP EP01934548A patent/EP1291438A1/en not_active Withdrawn
- 2001-06-05 JP JP2002502158A patent/JP4847668B2/ja not_active Expired - Lifetime
- 2001-06-05 CA CA002411850A patent/CA2411850A1/en not_active Abandoned
- 2001-06-05 WO PCT/JP2001/004734 patent/WO2001094618A1/ja not_active Application Discontinuation
- 2001-06-05 AU AU2001260716A patent/AU2001260716A1/en not_active Abandoned
- 2001-06-05 US US10/297,748 patent/US20040048387A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61280297A (ja) * | 1985-06-04 | 1986-12-10 | Noda Sangyo Kagaku Kenkyusho | アマドリ化合物の定量法及びその定量用試薬 |
JPH0556799A (ja) * | 1990-07-04 | 1993-03-09 | Nakarai Tesuku Kk | 糖化タンパク質の検出試薬 |
EP0709457A1 (en) * | 1994-10-05 | 1996-05-01 | Kyoto Daiichi Kagaku Co., Ltd. | Fructosyl amino acid oxidase and process for producing the same |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007163515A (ja) * | 2002-06-18 | 2007-06-28 | Asahi Kasei Pharma Kk | 糖化タンパク質測定用検量物質および標準測定法 |
JP2007107950A (ja) * | 2005-10-12 | 2007-04-26 | Bml Inc | 糖化アルブミンの管理試料 |
EP2352020A2 (en) | 2010-01-19 | 2011-08-03 | Arkray, Inc. | Method for analyzing sample by electrophoresis and use of the same |
CN109477839A (zh) * | 2016-07-28 | 2019-03-15 | 旭化成制药株式会社 | 糖化白蛋白的测定方法 |
CN109477839B (zh) * | 2016-07-28 | 2022-06-14 | 旭化成制药株式会社 | 糖化白蛋白的测定方法 |
WO2021002371A1 (ja) | 2019-07-01 | 2021-01-07 | 旭化成ファーマ株式会社 | フェロシアン化物の酸化還元電位を大きくするプロテアーゼの安定化剤を含む糖化タンパク質測定試薬、糖化タンパク質の測定方法、糖化タンパク質測定試薬の保存方法、及び糖化タンパク質測定試薬の安定化方法 |
WO2022158556A1 (ja) * | 2021-01-23 | 2022-07-28 | 株式会社Provigate | タンパク質の糖化度を評価する方法及び装置 |
Also Published As
Publication number | Publication date |
---|---|
US20040048387A1 (en) | 2004-03-11 |
JP4847668B2 (ja) | 2011-12-28 |
CA2411850A1 (en) | 2002-12-06 |
AU2001260716A1 (en) | 2001-12-17 |
EP1291438A1 (en) | 2003-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7393549B2 (en) | Defructosylation method | |
US20050133425A1 (en) | Sample preparation of biological fluids for proteomic applications | |
JP4834771B2 (ja) | ヘモグロビン消化用試薬 | |
JPH0559380B2 (ja) | ||
EP1889918B1 (en) | Analysis apparatus and analysis method for glycosylated hemoglobin | |
WO2001094618A1 (fr) | Procede de detection d'albumine saccharifiee | |
JP4183116B2 (ja) | 糖化タンパク質測定用検量物質および標準測定法 | |
JPH08228795A (ja) | 糖鎖分析用試料の調製方法及び該試料を用いた診断方法 | |
CN115433724B (zh) | 一种猪肝中提取5核苷酸酶方法 | |
JP4183197B2 (ja) | 糖化アルブミンの測定方法 | |
JP4622836B2 (ja) | 分析装置 | |
JP2008157905A (ja) | 添加法による生体試料中蛋白・ペプチドの定量方法 | |
JP5069023B2 (ja) | 糖化タンパク質測定用検量物質および標準測定法 | |
Baydanoff et al. | Non-enzymatic glycation of elastin | |
CN206975046U (zh) | 糖化血红蛋白检测试纸条 | |
Brunnekreeft et al. | Improved rapid procedure for simultaneous determinations of hemoglobins A1a, A1b, A1c, F, C, and S, with indication for acetylation or carbamylation by cation-exchange liquid chromatography | |
JP2007107950A (ja) | 糖化アルブミンの管理試料 | |
JP2003525451A (ja) | 生合成炭水化物欠損トランスフェリン対照標準 | |
Mogi et al. | Selective removal of beta 2-microglobulin from plasma specimens of long-term hemodialysis patients by high-performance immunoaffinity chromatography | |
JP3615428B2 (ja) | 蛋白結合型糖化蛋白を酵素免疫法で測定するための前処理方法 | |
CN115792045B (zh) | 一种门冬胰岛素中d-苏氨酸的检测方法 | |
JP2000178298A (ja) | グリコシル化および非グリコシル化タンパク質の分離法 | |
JP2573189B2 (ja) | カリクレインの検出方法 | |
Cooper et al. | Why the assay of serum cystine by protein precipitation and chromatography should be abandoned | |
CN116640741A (zh) | 一种从牛血清中提取肌酸激酶的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2411850 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001934548 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001934548 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10297748 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001934548 Country of ref document: EP |